Abstract |
Four monkeys were rendered parkinsonian by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ( MPTP) i.v. administration and then treated chronically with increasing doses of the D1 agonist CY 208-243 (0.05, 0.1 and 0.5 mg/kg). All animals showed a dose-dependent improvement of their parkinsonian signs after the chronic CY 208-243 treatment; however, half of them developed peak-dose dyskinesias. Dopamine levels were more decreased in the striatum of MPTP-monkeys with dyskinesias compared to those without dyskinesias. [3H] SCH 23390 and [3H] SKF 38393 binding to D1 receptors were in general similar in the striatum of both groups of MPTP-monkeys except [3H] SKF 38393 binding which was lower in the posterior putamen of dyskinetic compared to non-dyskinetic monkeys reflecting decreased coupling of this receptor to G proteins. [3H] spiperone and [3H] N-n-propylnorapomorphine binding to D2 receptors in the striatum tended in general to be higher in dyskinetic compared to non-dyskinetic monkeys, and this reached statistical significance in the posterior caudate labelled with [3H] n-propylnorapomorphine. [3H] muscimol binding to GABAA receptors was significantly higher in the posterior caudate of dyskinetic compared to non-dyskinetic monkeys. The extent of striatal DA denervation, decreased D1, elevated D2 and GABAA receptors, as well as the decrease of the D1/D2 receptor ratio in the posterior striatum may be involved in the appearance of dyskinesias after chronic CY 208-243 treatment.
|
Authors | C Gagnon, B Gomez-Mancilla, P J Bédard, T Di Paolo |
Journal | Neuroscience letters
(Neurosci Lett)
Vol. 163
Issue 1
Pg. 31-5
(Nov 26 1993)
ISSN: 0304-3940 [Print] Ireland |
PMID | 7905197
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Dopamine Agents
- Dopamine D2 Receptor Antagonists
- Indoles
- Phenanthridines
- Receptors, Dopamine D1
- Receptors, Dopamine D2
- Receptors, GABA-A
- CY 208-243
- 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- GTP-Binding Proteins
- Dopamine
|
Topics |
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(analogs & derivatives, pharmacology)
- Animals
- Autoradiography
- Behavior, Animal
(drug effects)
- Brain Chemistry
(drug effects)
- Dopamine
(metabolism)
- Dopamine Agents
(pharmacology)
- Dopamine D2 Receptor Antagonists
- Female
- GTP-Binding Proteins
(metabolism)
- Indoles
(pharmacology)
- Macaca fascicularis
- Neostriatum
(drug effects, metabolism)
- Ovariectomy
- Parkinson Disease, Secondary
(chemically induced, metabolism)
- Phenanthridines
(pharmacology)
- Receptors, Dopamine D1
(antagonists & inhibitors, drug effects)
- Receptors, Dopamine D2
(drug effects)
- Receptors, GABA-A
(drug effects)
|